Pharmacokinetics of Nafamostat Mesilate During Continuous Hemodiafiltration with a Polyacrylonitrile Membrane

Therapeutic Apheresis

Volumn 7, Issue 5, 2003, Pages 483-485

  Nakae, Hajime ^a   Tajimi, Kimitaka ^a  

^a AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous hemodiafiltration; Nafamostat mesilate; Polyacrylonitrile membrane

Indexed keywords

ANTICOAGULANT AGENT; GABEXATE MESILATE; HEPARIN; NAFAMSTAT MESILATE; POLYACRYLONITRILE;

ADULT; AGED; ANAPHYLAXIS; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTINUOUS HEMODIAFILTRATION; CORRELATION ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; FEMALE; HEMOFILTRATION; HUMAN; HYPERKALEMIA; MALE; MEMBRANE PERMEABILITY; MULTIORGAN DYSFUNCTION SYNDROME; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TIME; TISSUE DISTRIBUTION; ULTRAFILTRATION;

ACRYLIC RESINS; AGED; ANTICOAGULANTS; CATECHOLAMINES; DRUG INTERACTIONS; FEMALE; GUANIDINES; HEMODIAFILTRATION; HUMANS; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; MULTIPLE ORGAN FAILURE;

EID: 0242459574     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00088.x     Document Type: Article

References (18)

1. Nakae H, Yonekawa C, Wada H, Asanuma Y, Sato T, Tanaka H. Effectiveness of combining plasma exchange and continuous hemodiafiltration (combined modality therapy in a parallel circuit) in the treatment of patients with acute hepatic failure. Ther Apher 2001;5:471-5.
2. Nakae H, Asanuma Y, Tajimi K. Cytokine removal by plasma exchange with continuous hemodiafiltration in critically ill patients. Ther Apher 2002;6:419-24.
3. Ohtake Y, Hirasawa H, Sugai T et al. Nafamostat mesylate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 1991;93:215-7.
4. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. Nephron 1993;64:376-81.
5. Marshall JC, Cook DJ, Christou NV. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995;23:1638-52.
6. Fujii S, Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 1981;661:342-5.
7. Aoyama T, Ino Y, Ozeki M et al. Pharmacological studies of FUT-175, nafamostat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984;35:203-27.
8. Hitomi Y, Ikari N, Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 1985;15:164-8.
9. Kikuchi M, Endo S, Inada K et al. Inhibitory effect of FUT-175 on the production of interleukin 8 and polymorphonuclear leukocyte elastase. Res Commun Mol Pathol Pharmacol 1995;87:269-74.
10. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effect of nafamostat mesilate on pulmonary vascular injury induced by lipopolysaccharide in rats. Am J Respir Crit Care Med 1997;155:711-18.
11. Sugita H, Ishiko T, Ikei S, Hirota M, Ogawa M. FUT-175 inhibits the production of IL-6 and IL-8 in human monocytes. Res Commun Mol Pathol Pharmacol 1999;103:57-64.
12. Nakajima T, Kitajima I, Shin H et al. Involvement of NF-kappa B activation in thrombin-induced human vascular smooth muscle cell proliferation. Biochem Biophys Res Commun 1994;204:950-8.
13. Steinhoff M, Vergnolle N, Young SH et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-8.
14. Hoogerwerf WA, Zou L, Shenoy M et al. The proteinase-activated receptor 2 is involved in nociception. J Neurosci 2001;21:9036-42.
15. Hirasawa H. Protease inhibitor as anticoagulant for blood purification. J Clin Exp Med (Igaku No Ayumi) 2001;198:113-18 (in Japanese).
16. Nakanishi Y, Inagaki O, Hiwasa K, Hiraoka K, Takamitsu Y. Adsorption of charged drugs by dialysis membranes. Jpn J Artif Organs 1996;24:113-16 (in Japanese).
17. Muto S, Imai M, Asano Y. Effect of nafamostat mesilate on Na+ and K+ transport properties in the rabbit cortical collecting duct. Br J Pharmacol 1993;109:673-8.
18. Kitagawa H, Chang H, Fujita T. Hyperkalemia due to nafamostat mesilate. New Eng J Med 1995;332:678.